Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer

BACKGROUND: The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA– (ctDNA-) based copy number alterations (CNAs) to determine treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Meijun, Tian, Yijun, Tan, Winston, Wang, Liewei, Wang, Liguo, Kilari, Deepak, Huang, Chiang-Ching, Wang, Liang, Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501185/
https://www.ncbi.nlm.nih.gov/pubmed/32203070
http://dx.doi.org/10.1038/s41391-020-0224-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501185/
https://www.ncbi.nlm.nih.gov/pubmed/32203070
http://dx.doi.org/10.1038/s41391-020-0224-4

Ejemplares similares